



## Novalyst Discovery and AliX agree to merge NovAliX launch

### Integrating structural biology and medicinal chemistry

Strasbourg, September 15th, 2008. Following long-standing cooperation, Novalyst Discovery, a chemistry services company, and AliX, a structural biology company, have agreed to merge to create a leading CRO. Together they have launched NovAliX, a multidisciplinary company providing flexible outsourcing solutions for drug discovery and development.

The combined company will represent a major provider able to deliver comprehensive services from gene to preclinical drug candidates and especially offering alternative fragment-based drug discovery approaches.

*"There was a natural synergy between the two companies whose expertise in chemistry and structural biology brings a valuable set of skills for our drug discovery program",* claimed Stephan Jenn, President of both companies. *"In the past, opportunities for joint programs have shown us that we were able to integrate our highly complementary expertise to conduct projects successfully."*

Since the beginning of 2008, both companies have been combining operations to facilitate the organizational process. *"Our priority is to ensure that our clients receive even greater support as we go forward as one company."* In a competitive and demanding environment the combined company NovAliX will be a larger, stronger and more integrated organization offering clients access to a wider range of capabilities all the more since the integrated platform of comprehensive biological and chemical services is advantageously complemented by a high-value added screening technology. Indeed NovAliX has developed a unique and innovative platform using non-covalent mass spectrometry for compound screening and binding characterization. This mass spectrometry technology has emerged as an alternative and efficient technique for delivering high-content information on compound-protein interactions. Using this sensitive technique known as FAMASS™ (Fragments Analysis by MAss Spectrometry) in combination with its in-house fragment library, NovAliX proposes fragment-based drug discovery programs, a cost-effective approach for fast lead generation. Information about integrated drug discovery research services can be found at [novalix-pharma.com](http://novalix-pharma.com)

#### **About NovAliX**

NovAliX is a contract research organization. Through a set of capabilities including protein delivery, X-ray protein structure determination, custom synthesis, chemistry R&D, medicinal chemistry and molecular modeling, NovAliX offers comprehensive services in research and development of small molecules. NovAliX, a team of 60 scientists, is located in state-of-the-art laboratory facilities (1600 m<sup>2</sup>) in the Strasbourg-Illkirch science cluster.

#### **Contact**

NovAliX

Anne Briot-Dietsch, PhD

BioParc, Boulevard Sebastien Brant, F-67400 Illkirch, France

[info@novalix-pharma.com](mailto:info@novalix-pharma.com)

[www.novalix-pharma.com](http://www.novalix-pharma.com)